Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharming Technologies B.V.
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent must be obtained before any assessment is performed.
Paients must have participated in the study CCDZ173X2201 or were treated previously with PI3Kδ inhibitors other than CDZ173.
Patients who are deemed by the Investigator to benefit from PI3Kδ inhibitor therapy.
Patients or their legal representatives (for patients under the age of 18 years) must be able to communicate well with the Investigator, to understand and comply with the requirements of the study.
